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ANALYSIS OF ESSENTIAL THROMBOCYTHEMIA AND ITS TREATMENT  
 
CADE ALAN COWART 
ABSTRACT 
Essential thrombocythemia (ET) is a rare myeloproliferative neoplasm affecting 43.7 out 
of every 100,000 people in the United States. The disease is characterized by abnormally 
high platelet counts, mutational abnormalities in Janus Kinase 2 (JAK2)/Calreticulin 
(CALR)/myeloproliferative leukemia virus oncogene (MPL), and increased 
megakaryocyte production and differentiation. The average age of onset for patients with 
ET is between 65-70 years, but recent studies have demonstrated a downward trend in the 
age of diagnosis. Mechanistically, ET mutations cause the dimerization of JAK and 
upregulation of the JAK-STAT pathways. Common treatment approaches seek to use 
cytoreduction and platelet inhibition to lower the risk of a thrombotic event. Hydroxyurea 
and low-dose aspirin have been the gold-standard of treatment for ET patients. This thesis 
sought to compare the current available therapy with second-line treatments and 
investigational treatments. Anagrelide is a key second-line treatment for ET that is used in 
the event of intolerance to hydroxyurea. It acts through cytoreductive mechanisms which 
result in a decreased platelet count. Major bleeding is a severe adverse event associated 
with anagrelide. Interferons are another second-line defense in the treatment of ET despite 
a lack of FDA approval for this indication. Interferons act directly to reduce platelet counts 
and, unlike other drug classes, mount an immunological response against the JAK2 stem 
cells to reduce the allelic burden. An immunological approach to ET may be key to the 
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sustained treatment of the disorder without a daily dosing regimen. Despite the promise of 
interferons, severe adverse effects limit the adherence of many patients to this class of 
drugs. JAK inhibitors are an investigational drug class that acts directly through the JAK-
STAT pathway. JAK inhibitors have shown little efficacy in the treatment of ET and may 
be better suited for treatment in combination therapies. Telomerase inhibitors are one such 
investigational drug class that may pair well with JAK inhibitors for the treatment of ET. 
All of these drug classes were compared to hydroxyurea with respect to their 
pharmacokinetics, pharmacodynamics, and patient evaluation. Hydroxyurea and low-dose 
aspirin showed superiority in comparison to other drug classes due to their low toxicity 
profile and minimum adverse side-effects, high oral bioavailability and wide distribution, 
high adherence, and production of the most uniform response to reducing thrombotic 
events and platelet counts. The interferon drug class shows unique potential for the 
treatment of ET and should be placed above the second-line treatment standard of 
anagrelide due to its benefits in treatment of younger and pregnant patients. Interferons are 
the only class of drug for the treatment of ET that did not increase the risk of drug-related 
leukemogenic transformations. Despite non-adherence due to side-effects and lack of an 
oral administration, interferons are superior to anagrelide due to their longer dosing interval 
and immunological attack on JAK2 stem cells. Treatment of ET with anagrelide has shown 
similar efficacy to hydroxyurea and interferons in platelet reduction and rivals hydroxyurea 
in the prevention of thrombotic risk. Despite this benefit, the risk of bleeding associated 
with anagrelide is a significant disadvantage. Hydroxyurea and low-dose aspirin remain 
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the current standard of treatment for patients with ET, although new approaches may soon 
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 In the first part of this thesis a brief overview and history of essential 
thrombocythemia (ET) will be provided. The criteria for diagnostics and the recent changes 
brought forth by the World Health Organization will be examined and explained to further 
understand the complexity of this disorder. An in-depth review of the mutations and 
etiologies will be assessed to form a better understanding of the mechanistic actions of 
pharmacologic treatments. A detailed discussion into the prognosis and incidence rates of 
ET will also be reviewed. The next part of the thesis will compile a comprehensive list of 
the current and novel pharmacological treatments for ET and evaluate them both in 
monotherapy and in combination. A conclusion will be drawn about the best available 
therapy after careful consideration of pharmacokinetics, pharmacodynamics. patient 
evaluation, and side effects. Non-adherence rates for each type of therapy will also be 
considered, as rates in patients on cytoreductive treatments is reportedly as high as 28% 
and is especially high in younger patients where route and schedule of drug administration 
are key factors (Le Calloch et al. 2018).  
Brief Overview and History of Essential Thrombocythemia 
Essential thrombocythemia is a rare myeloproliferative neoplasm (MPN) affecting 
roughly 1.18 out of every 100,000 people in the United States (Shallis et al. 2020). Since 
the discovery of myeloproliferative diseases in 1951 by William Dameshek, ET is one of 
the four classical hematopoietic tumors (Dameshek 1951). Polycythemia vera (PV) and 
primary myelofibrosis (PMF) being two other classical hematopoietic tumors that are more 
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closely related to ET in that they are classified as Philadelphia chromosome negative 
myeloproliferative neoplasms (Shallis et al. 2020). The last of the classic four 
myeloproliferative neoplasms is chronic myeloid leukemia (CML), which is classified as 
Philadelphia chromosome positive (Shallis et al. 2020).  
 There has been much debate over the years since its discovery in 1951 as to why 
the incidence of ET is rising. As the World Health Organization (WHO) changes and 
revises the diagnostic criteria for MPN’s, the diagnoses have become more specific to each 
MPN. A study published in France in 2009 showed that there was an increase in the 
incidence of ET during 2005 to 2007 when compared to the 1980 to 2004 incidence rate 
(François Girodon et al. 2009). They theorized that the slight increase in incidence rates 
from 1.2 to 3 per 100,000 inhabitants on the World Standard Population, were due to the 
2008 WHO revisions of MPN diagnostic criteria (François Girodon et al. 2009). However, 
a more recent study published in 2020 uses the 2016 WHO revisions and has demonstrated 
that the incidence rates from 2001 to 2016 for all MPNs, have remained stable, as seen in 





Figure 1. Incidence of Essential Thrombocythemia in Male and Female Patients. This 
image shows data collected from the Surveillance, Epidemiology, and End Results (SEER) 
study regarding the annual incidence of ET during 2001 to 2016. These data show the 
incidence of newly diagnosed ET in male, female, and all patients per 100,000 subjects on 
an annual basis. In recent years the incidence of ET in the general population appears to 
have remained stable with a slight dip in the last year 2016. Image adapted from Shallis et 
al. 2020. 
 
 The most recent revision of diagnostic criteria for ET and the other MPNs occurred 
in 2016 and has since produced changes in the treatment of MPNs. As new evidence is 
compiled on the diagnostic characteristics of the MPNs and new mutations are found, 
therapeutic discoveries are closing in on improving the quality of treatments. The 
Philadelphia chromosome negative MPNs are now known to be associated with three 
different molecular drivers: JAK2, CALR, and MPL (Grinfeld et al. 2018). Recent studies 
have shown that targeting these pathways could lead to more specific therapies and better 





CHARACTERISTICS OF ESSENTIAL THROMBOCYTHEMIA 
 
Diagnostic Criteria for Essential Thrombocythemia 
The most recent 2016 WHO revisions classify ET as having four major criteria or three 
major criteria and one minor criteria. The major criteria for ET include platelet counts in 
excess of or equal to 450 x 109/L, proliferation of bone marrow megakaryocytes and loose 
clusters, Janus Kinase 2 (JAK2)/Calreticulin (CALR)/myeloproliferative leukemia virus 
oncogene (MPL) mutations, and not meeting the criteria of other myeloid neoplasm. The 
minor criteria required another clonal marker present (Tefferi and Barbui 2019). Other 
clonal markers that may aid in the diagnosis of ET is a polyclonal activation pattern in T 
cells but not granulocytes or platelets (Briere and El-Kassar 1998). Ruling out the 
possibility of reactive thrombocytosis from secondary causes such as trauma or infection 
that may cause platelet counts higher than 450 x 109/L is another alternative minor 
criterion. A bone marrow biopsy is the most accurate approach for diagnosing and 
distinguishing ET from other MPNs (Tefferi and Barbui 2019). This criteria is significantly 
different from that of the 2001 revision in that the platelet count was required to be in 
excess of 600 x 109/L and that of the 2008 revision in which the JAK2-V617F mutation 
was only required for PV diagnosis (Shallis et al. 2020). 
Diagnosis of ET in patients presents as characteristic elevated platelets and 
potentiates risk of thrombosis and an increased risk of aggregation of platelets (Pedersen 
et al. 2018). Figure 2 illustrates the increased number of platelets characteristic of ET. It is 
worth noting that while blood smears are not a single determinant of ET, they are used for 
initial diagnosis of thrombocytosis with a confirmation by bone marrow biopsy. It is from 
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this point that the doctor may begin diagnosis of ET through the given criteria and 
elimination of other MPNs. 
 
Figure 2. Peripheral Blood Smear of Patient with ET. The image shows a Wright’s stain 
taken from a patient with ET. There are notably higher platelet counts at the time of 
diagnosis. A few examples of platelets have been indicated by arrows. Image taken from 
Byun et al. 2014. 
 
Megakaryocyte and Platelet Production Before Essential Thrombocythemia 
  To understand the nature and treatment of ET it is best to understand 
megakaryocyte and platelet production under normal circumstances. Thrombopoietin is the 
growth-factor responsible for the megakaryocyte lineage (Deutsch and Tomer 2006). The 
binding of thrombopoietin to the c-Mpl receptor signals the maturation of megakaryocyte 
progenitors which give rise to platelets (Deutsch and Tomer 2006). Megakaryocytes are 
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produced in the bone marrow from hematopoietic stem cells (Deutsch and Tomer 2006). 
Regulation of megakaryocyte differentiation occurs through thrombopoietin at the c-Mpl 
receptor, in response to decreased platelets that bind free thrombopoietin, preventing its 
binding to the c-Mpl receptor (Deutsch and Tomer 2006). It is important to understand this 
fundamental mechanism of megakaryocyte and platelet production as it is key in the 
overproduction of platelets characteristic with ET. 
Mutations and the Molecular Mechanisms of Essential Thrombocythemia 
The first major break-through in the treatment of ET occurred with the differentiation 
between CML and the other three MPNs. CML is a Philadelphia chromosome positive 
disorder while ET is a Philadelphia chromosome negative disorder (Shallis et al. 2020). 
The translocation of the short arms of chromosome 22 to chromosome 9 results in a shorter 
than normal chromosome 22, giving rise to the new gene, BCR-ABL1 (Arber et al. 2016). 
This mutation gives rise to hematopoietic stem cell proliferation through the tyrosine-
kinase pathway in CML. ET mutations give rise to similar hematopoietic stem cell 
proliferation but act through different mutations all of which activate the Janus kinase 
pathway (Arber et al. 2016). 
The Janus Kinase family (JAK) consists of three JAKs (1-3) and Tyrosine kinase 2 
(Hubbard 2018). Together they serve as activators through important cytokine receptors 
such as interleukins, interferons, growth hormones, erythropoietin and leptin (Hubbard 
2018). When one of these signals binds to the extracellular receptor of a JAK, dimerization 
between the two JAK components occurs (Hubbard 2018). Trans-phosphorylation of the 
two dimer pieces activates the JAKs which can then phosphorylate signal transducer and 
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activator of transcription (STAT) (Hubbard 2018). STAT then can enter the nucleus and 
cause changes in transcription which may upregulate activity (Hubbard 2018).  
One of ETs characteristic mutations needed for diagnosis is a JAK2 mutation at the 
JAK2 V617F location of hematopoietic cells (Arber et al. 2016). The pathological nature 
of this mutation is thought to have relevance in the JH2 domain (orange region) of JAK2, 
as seen in Figure 3 below (Hubbard 2018). JH1 (blue region) is the domain responsible for 
trans-phosphorylation and therefore stabilization of the JAK2 (Hubbard 2018). The JH2 
domain acts as the autoinhibitory mechanism when there are cytokines (Hubbard 2018). In 
the presence of the JAK2 V617F mutation when there are no cytokines the JH2 domain is 
thought to act as mediator for dimerization of the JAK2 (Hubbard 2018). This in turn will 
activate JH1 and the JAK pathway (Hubbard 2018). The activation of the JAK2 pathway 
leads to an increase in the cellular proliferation lines of hematopoietic cells (Salhorta and 
Oo 2014). In the presence of the JAK2 V617F mutation the increased production of 
hematopoietic cells can be associated with elevated platelet counts, leukocytosis, and bone 





Figure 3. Mechanism of JAK2 and V617F Mutation. Part A of the image shows the 
addition of cytokines (magenta) upon the extracellular JAK2 regions (grey) to induce the 
change in a normal functioning JAK2. The four domains of the JAK2 are FERM (green), 
SH2L (yellow), JH2 (orange), and JH1 (blue). Part B shows the capacity for the V617F 
(red star) mutation to stabilize the activated JAK2 through the JH1 domains in the absence 
of cytokines and initiate the phosphorylation sequence. The red arrow indicates the 
preference of the JH1 domain to remain active in the presence of the mutation. The 
mutation creates a ligand independent JAK. Image adapted from Hubbard et al. 2018. 
 
There are other mutations though that can arise and result in diagnosis of ET in a JAK2 
V617F negative patient. These mutations can occur in calreticulin (CALR) or 
myeloproliferative leukemia virus oncogene (MPL) as driver mutations (Araki and 
Komatsu 2020). The CALR mutation was discovered in 2013 and its role in ET has since 
been defined. The CALR mutation is a calreticulin (CALR) that encodes for a mutant 
chaperone located in the endoplasmic reticulum (Araki and Komatsu 2020). The mutation 
is caused by a frameshift in exon 9 from either nucleotide insertion or deletion and results 
in a gain of function which acts to inhibit the proline-rich section that typically would 
inhibit the thrombopoietin receptor MPL (Araki and Komatsu 2020). The domain at which 
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the frameshift occurs is the C-terminus where the wild-type CALR contains a series of 
negatively charged amino acids; the mutant form of CALR is replaced by positively 
charged amino acids (Araki and Komatsu 2020).  
The CALR mutation involving chromosome 9 acts by granting cytokine-independent 
growth to cells through the thrombopoietin receptor which is activated by thrombopoietin 
(TPO) (Araki and Komatsu 2020). In the wild-type, MPL would be inhibited by a proline-
rich segment on the gene product but, the CALR mutation removes this inhibition through 
the addition of another in-gene inhibitor that acts to block the proline-rich segment’s 
activity (Araki and Komatsu 2020). The increased thrombopoietin receptor activation will 
cause activation of the JAK2 pathway which is independent of the JAK2 V617F mutation 
(Araki and Komatsu 2020).  
Mutations in the thrombopoietin receptor gene (MPL) may also occur independently 
of the CALR mutations. The MPL mutation can occur at many different locations within 
the CALR gene, with W515L and W515K being the most common and W515A, W515R 
and S505N being the least common (Elsayed, Ranavaya, and Jamil 2019). These mutations 
have been shown to increase the receptor sensitivity to TPO (Elsayed, Ranavaya, and Jamil 
2019). The activation of hypersensitive MPL receptor will now activate the JAK2 pathway 
when TPO binds. This in turn will produce the upregulation of megakaryocytes, platelet 
production, and other hemopoietic stems cells independently of the amount of the TPO 
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Table 1. Overview of ET-associated mutations and Wild-type Genes. The table 
illustrates the different genetic mutations that are associated with ET as well as the wild-
type function and production. The mutations have similar results of ET symptomology with 
elevated platelet counts but the pathways and functions of the mutations vary. 
 
 
Prognosis and Etiology of Essential Thrombocythemia 
In order to estimate survival rates of patients with ET doctors have created the 
International Prognostic Score for ET (IPSET). The IPSET uses a series of diagnostic 
factors to create a score for the severity of risk based on a point system. Age, leukocytosis, 
and history of thrombosis are the key features in the IPSET score but other independent 
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factors such as sex have also been identified to shorten survival of patients with ET (Tefferi 
et al. 2017). 
 ET may occur at any age but is predominantly diagnosed between the ages of 65-
70 years old (Brière 2007). A more recent publication found that the average age of 
diagnosis is decreasing to around 58 years. The study used data collected from 1076 
patients in the Mayo Clinic (Tefferi and Pardanani 2019). These discrepancies in data may 
be due to changes in the diagnostic standards of the WHO and recent updates in technology. 
Age of diagnosis does seem to show a significant difference in prognosis though. Those 
diagnosed at age 60 years and older showed markedly decreased life spans and are placed 
into high risk categories for thrombosis and leukemic transformations (Tefferi and 
Pardanani 2019). A diagnosis at age of 50 years and younger led to a normal life span and 
appeared to have no significant threats within the first decade following diagnosis, 
however, longer follow ups did reveal shorter lifespans and more complications than their 
healthy counterparts (Tefferi et al. 2017). The Mayo Clinic study on MPNs revealed that 
patients with ET may have an average overall survival of 18 years (Szuber et al. 2019). As 
data is compiled and more risk assessments completed, it can be concluded that the life 
span and survival of ET patients are significantly shortened when compared to those 
without ET.   
 One major risk that ET patients face is the threat of thrombotic complications. It 
therefore makes sense that a previous history of thrombosis would place patients in higher 
risk categories and shorten the survival chances of these patients (Tefferi 2012). One study 
performed by Stefano et al. (2008) showed that after one thrombotic event the likelihood 
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of a reoccurrence was 5.9% in patients <60 years old and 8.9% in patients >60 years old 
(Stefano et al. 2008). Thrombotic events for this study were defined as ischemic strokes, 
transient ischemic attacks, acute myocardial infarction, unstable angina pectoris, peripheral 
arterial thrombosis, retinal artery/vein occlusion, deep venous thrombosis, and pulmonary 
embolism (Stefano et al. 2008). A patient with an age greater than 60 years old and history 
of thrombotic events has a 1.7 times increased risk of reoccurrence (Stefano et al. 2008). 
The study used a retrospective design, following patients between the years of 1985 to 
2005 at major hematology centers (Stefano et al. 2008). A thrombotic event was required 
to be reported if it occurred within the 2 years before the diagnosis of the patient or after 
the referral to the hematology center (Stefano et al. 2008). Their data concluded that major 
risk factors for a reoccurrence of thrombotic events and therefore a decreased prognosis 
was an age over 60 years with prior history of thrombosis (Stefano et al. 2008). 
 Hyperleukocytosis, a white blood cell count of 15 x 109/l, was reported to be 
associated with a worse prognosis if found at time of diagnosis with ET (F. Girodon et al. 
2010). Gangat et al. (2007) found similar results as well as confirmed the strong correlation 
between low hemoglobin and hyperleukocytosis in predicting a low prognostic value for 
ET patients. Based on a multivariate analysis, leukocytosis and low hemoglobin, used 
together with the age variable and a platelet count of 1000 x 109/l, showed a lower 
prognostic score than when compared to patients lacking these (Gangat et al. 2007).  
 Gender also plays a key role in the prognostic score of ET patients. Women, 
particularly those diagnosed at older ages, were found to have a longer survival rate and 
better prognostic score and less complications resulting in premature death, than their male 
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counterparts (Tefferi et al. 2017). The findings were further indicative of a difference 
between sexes based on a multivariate analysis of the IPSET risk categories comparing 
high-risk, intermediate-risk, and low-risk men and women with ET (Tefferi et al. 2017). In 
the high-risk IPSET category, men were shown to have the highest survival disadvantage 
when compared to their women counterparts (Tefferi et al. 2017). Women were more likely 
to receive a diagnosis though than men with 67% of the patients diagnosed in a Mayo Clinic 
study being women (Tefferi and Pardanani 2019). It is estimated that ET’s ratio is two 
females to every one male (Brière 2007). While gender does seem to be a factor in the 
prognostic score of ET, there is no evidence that it has any significance in the leukemic 








Figure 4. Survival Years by Gender of Patients with ET. This graph indicates the years 
of survival after diagnosis of males (red) and females (black) with ET. The median 
population age of the surveyed 904 patients was 58 years old (18-96 years old) and 65% 
of the population was female. Women appear to be diagnosed later than their male 
counterparts with an average female diagnosis occurring between 58 to 6o years of age and 
a male diagnosis occurring around 56 to 58 years of age. The median survival after 
diagnosis of ET is 14 year in men and 20 years in women. Image taken from Tefferi et al. 
2017. 
 
Mutation’s Differing Effects on the Prognosis and Etiology of Essential 
Thrombocythemia 
 Each mutation profile can yield a different subtype of ET in patients and present 
with different stratifications of the disorder. Kim et al. (2015) sought to analyze the 
different mutation profiles and disease subgroups. In the 199 patients that the study 
reviewed 79 were diagnosed with ET (Kim et al. 2015). The mutation profiles of these 
patients showed that 50 (63.3%) had the JAK2 V617F mutation, 9 (11.4%) had the type 1 
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CALR frameshift, 5 (6.3%) had the type 2 CALR frameshift, only 2 (2.5%) had the MPL 
mutation, and 13 (16.5%) were triple negative (Kim et al. 2015).  
Patients with the CALR mutations had profiles that tended to be more male 
predominant with lower leukocytosis and hemoglobin levels, but higher platelet counts 
than patients with JAK2 mutations (Kim et al. 2015). These values were compared to their 
JAK2 mutated counterparts. The CALR mutation profile placed ET patients in a lower risk 
category on the prognosis scale (Kim et al. 2015). The results from Kim et al. (2015) 
supports a similar study conducted by Rumi et al. (2014). The study showed that patients 
with the JAK2 mutation were in fact older, had higher leukocytosis and hemoglobin levels, 
and lower platelet counts when compared to their CALR counterparts (Rumi et al 2014). 
This study reviewed 745 ET patients of whom, 466 (62%) had the JAK2 V617F mutation, 
176 (24%) had the CALR exon 9 mutation, 28 (4%) had the MPL exon 10 mutation, and 
75 (10%) were triple negative (Rumi et al. 2014). It is worth noting that this study 
determined a significant proportion of ET patients with the JAK2 V617F mutation 
progressed to PV while none of the CALR patients did. This finding shows that the CALR 
mutation results in a different disease profile from that of the JAK2 mutation (Rumi et al. 
2014). Further research on treatment efficacy in patients stratified by their mutation profiles 

















Kim et al. 50 (63.3%) 14 (17.7%) 2 (2.5%) 13 (16.5%) 79 
Rumi et al. 466 (62%) 176 (24%) 28 (4%) 75 (10%) 745 
Table 2. Comparison of Mutation Profiles from Two Separate Studies. The table above 
illustrates the similar percentages of mutation types found in patients with ET from two 
different studies despite the smaller sample size of the first study. The geographic locations 
of the studies varied differed as well with Rumi et al. conducting their study in Italy and 
Kim et al. conducting their study in South Korea. 
 
An Overview of the Treatments for Essential Thrombocythemia  
 When viewed in clinical practice, the physician may have a few options for the 
treatment of ET. As seen earlier in the risk stratification levels determined by the IPSET 
criteria, a patient may be low risk, intermediate risk, or high risk (Tefferi and Pardanani 
2019). Each stratification comes with its own diagnosis and prognosis; therefore, it should 
make sense that treatment will vary with each level.  
 If the patient presents at the lowest level of risk stratification with little to no risk 
of a cardiovascular event, the clinician may decide on only monitoring the current platelet 
and hemoglobin counts (Tefferi and Pardanani 2019). Should the patient move to a higher 
risk level, the clinician may select a treatment of low-dose aspirin and hydroxyurea to 
reduce risk of thrombosis, as this combination produces efficacy with lower side effects 
than other cytoreductive therapies (Tefferi and Pardanani 2019).  
 Should a patient acquire intolerance to hydroxyurea as a first-line drug, there are 
other treatment options available for ET (Tefferi and Pardanani 2019). Anagrelide is a 
second-line drug approved by the FDA for treatment of ET in the event of intolerance to 
hydroxyurea (Tefferi and Barbui 2019). Based on several comparative studies of anagrelide 
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vs hydroxyurea, it has been determined that hydroxyurea is the better choice as a first-line 
drug for ET (Tefferi and Pardanani 2019).  
In more recent years as research on ET has increased, many new drugs have begun 
to surface as potential candidates for treatment. Pegylated Interferon-alfa 2a is one such 
drug that causes a substantial reduction in hematocrit levels, but the risk of side effects is 
still being assessed (Tefferi and Barbui 2019). Alkylating agents like busulfan have often 
been considered a last resort option for patients with advanced ET and hydroxyurea 
intolerance (Tefferi and Barbui 2019). Other potential candidates include JAK inhibitors 
like ruxolitinib and momelotinib as well as telomerase inhibitors like imetelstat (Tefferi 
and Barbui 2019). Histone-deacetylase inhibitors are also novel drug candidates that have 
been shown to reduce ET allele burden and other symptoms (Gunawan et al. 2018). The 
allelic burden is a concept referring to the proportion of mutant genes to wild-type in the 
JAK2 hematopoietic stem cells. Higher counts of mutated cells lead to a higher risk of 
symptoms (Passamonti and Rumi 2019). Reducing the proportion of mutated 
hematopoietic stem cells lowers the population of abnormal cells that lead to excessive 
platelet counts and increased risk of thrombosis (Passamonti and Rumi 2009). 
It is important to note that due to its low prevalence, ET falls under the category of 
an “orphan disease” and is therefore covered by the Orphan Drug Act. According to the 
FDA an orphan disease is one that effects fewer than 200,000 patients and thus qualifies 
for tax cuts and 50% payment of research on drug treatments through federal grants and 
programs (Commissioner 2019). This federal program incentivizes research for rare 
diseases that may not be able to attract large nongovernmental funding. Almost all of the 
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EVALUATION OF CURRENT AND POTENTIAL DRUG TREATMENTS 
 
Low-Dose Aspirin and Cytoreductive Hydroxyurea 
 The standard first-line treatment for essential thrombocythemia is administration of 
low-dose aspirin (81 mg) and hydroxyurea because of their low side effect profiles, good 
efficacy, oral administration route, and low intolerance rates (Tefferi and Pardanani 2019). 
Patients at the low risk level of ET are usually monitored by health care providers or started 
on a daily low-dose treatment of aspirin alone (Tefferi and Pardanani 2019). In more severe 
cases of ET the doctor may decide to place the patient on a daily regimen of hydroxyurea 
and low-dose aspirin (Tefferi and Pardanani 2019).  
Aspirin inhibits platelet activation while hydroxyurea targets DNA synthesis 
directly. Once taken, the mechanism of action of hydroxyurea involves a conversion to a 
free radical nitroxide which is taken up by proliferating megakaryocytes (Yarbro 1992). 
The free radical binds at the active site of ribonucleotide reductase in the proliferating 
megakaryocytes preventing the formation of deoxyribonucleotides from ribonucleotide 
precursors and therefore selectively inhibiting DNA synthesis (Yarbro 1992). Cell death 
during the S phase is produced and there is a reduction in the number of circulating 
megakaryocytes, termed cytoreduction (Yarbro 1992). Hydroxyurea also works to inhibit 
DNA repair (Yarbro 1992). The mechanism for aspirin involves the acetylation of 
cyclooxygenase in the platelets (Schrör 1997). The acetylation of the serine in the 
cyclooxygenase prevents arachidonic acid from binding at the binding site and forming 
thromboxane (Schrör 1997). Without thromboxane the platelets cannot be activated and 
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aggregation cannot occur (Schrör 1997). This irreversible, long-lasting inhibition of 
platelet cyclooxygenase helps prevent the formation of thromboses.  
 In recent studies of low-dose aspirin and ET there has been much debate on the 
exact regimen to follow for required platelet suppression. The treatment of ET following a 
thrombotic event may change the drug of choice for platelet suppression (Landolfi and 
Gennaro 2008). Clopidogrel may be a drug of choice following an acute coronary 
syndrome while dipyridamole may help in the event of ischemic strokes or transient 
ischemic attacks (Landolfi and Gennaro 2008). The safety and efficacy of these drugs has 
not been assessed in enough detail with ET patients taking cytoreductive drugs and more 
data are needed (Landolfi and Gennaro 2008). Once daily low-dose aspirin defined as 81 
mg, while a useful treatment, seems to lack the ability to combat the high platelet turnover 
of ET (Larsen et al. 2019). Studies on patients with ET have shown that a regimen of low-
dose aspirin given twice daily may prove more beneficial. In one such study by Larsen et 
al. (2019), they were able to show that twice daily low-dose aspirin increased platelet 
inhibition, proving to have a more consistent effect than once-daily treatments in patients 
with ET. Their data compared ET patients using first the once daily treatment for 7 days 
and then, after a 14-day aspirin washout, a twice daily 7-day regimen (Larsen et al. 2019). 
The findings showed lower thromboxane B2 and platelet aggregation in the group treated 
twice daily (Larsen et al. 2019). Aggregation was assessed using whole blood impedance 
aggregometry with arachidonic acid as the agonist and thromboxane B2 was measured 
using an enzyme linked immunosorbent assay (Larsen et al. 2019). Another similar study 
by Rocca et al. (2020), used three dosing regimens in patients with ET; once daily, twice 
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daily, and three times daily low-dose aspirin. Their study showed that the twice daily and 
thrice daily regimen significantly reduced thromboxane B2 when compared with the once 
daily regimen after two weeks of 100 mg daily dosing (Rocca et al. 2020). The study further 
showed that while the thrice daily did reduce thromboxane B2 more than the twice daily, 
the abdominal discomfort score for the thrice daily regimen was higher (Rocca et al. 2020). 
Their data indicate that once daily dosing regimen for patients with ET is not as effective 
in reducing platelet activation as the twice daily and any further reductions in dosing 
regimen did not significantly reduce platelet activation (Rocca et al. 2020). While both 
studies failed to report any evidence on major side effects outside of abdominal pain, Bhatt 
et al. (2008) showed some of the adverse side-effects associated with low-dose aspirin. 
Patients who take low-dose aspirin should be aware of an increased risk of upper 
gastrointestinal bleeding and abdominal discomfort. Dosing over 81 mg for long-term use 
may not be recommended (Bhatt et al. 2008). 
 In a study conducted by Rodriguez et al. (1998) on the pharmacokinetics of orally 
administered hydroxyurea compared to intravenous hydroxyurea in 29 patients with solid 
malignancies, the Tmax was found to be 1.22 hours with a delay in appearance of 0.22 hours 
for the oral drug (Rodriguez et al. 1998). This indicates a relatively rapid absorption rate 
with the peak plasma concentration reaching 794 μmol/L after a 2000-mg oral dose 
(Rodriguez et al. 1998). The bioavailability for oral hydroxyurea was found to be complete 
at around 100% (Rodriguez et al. 1998). Hydroxyurea was excreted via renal and nonrenal 
methods and has a clearance of 7.7 L/hour (Rodriguez et al. 1998). The distribution was 
found throughout all tissues but was concentrated in erythrocytes and leukocytes 
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(Rodriguez et al. 1998). Drug in the plasma was 75-80% bound to plasma proteins 
(Rodriguez et al. 1998). The dosing regimen for this study used 80 mg every three days for 
three weeks totaling to 2000 mg orally (Rodriguez et al. 1998).  
Hydroxyurea is typically given in dosages ranging from 15-20 mg/kg/day with the 
appropriate dosing regimen dependent on platelet values (Finazzi and Barbui 2001). 
Studies show that the median length of time for the onset of treatment efficacy varies 
depending on platelet counts but high risk patients were reported to have satisfactory 
platelet counts after a median of 30 days (Cortelazzo et al. 1995). 
 Toxicity and severe adverse side effects due to hydroxyurea are reportedly rare but 
more recent studies have shown this may not always be the case. Some studies have 
analyzed the claims of hydroxyurea increasing the transformation rate to acute leukemia. 
The findings of Finazzi and Barbui (2001) indicate the risk of acute leukemic transition in 
older patients with high-risk profiles is outweighed by the potential benefits of 
hydroxyurea. There is still much debate over the use of hydroxyurea in younger patients 
with low-risk profiles though (Finazzi and Barbui 2001). Nielsen and Hasselbach’s (2003) 
research on leukemic transformation used data collected from 83 patients, 58 of these 
patients were treated with hydroxyurea and 18 of them had received hydroxyurea and 
busulphan. Follow-ups were conducted for an average of 7.8 years and any incidence of 
transformation to acute myeloid leukemia or myelodysplasia was noted (Nielsen and 
Hasselbalch 2003). Their research suggests that hydroxyurea has leukemogenic tendencies 
and increases risk of acute myeloid leukemia transformation by 14% (Nielsen and 
Hasselbalch 2003). This risk is severely increased to 30% if busulphan, another form of 
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chemotherapy, is used before treatment with hydroxyurea (Nielsen and Hasselbalch 2003). 
They concluded that hydroxyurea is not recommended in younger patients due to acute 
leukemic transformation after extended usage (Nielsen and Hasselbalch 2003). 
  Hydroxyurea has also been associated with cutaneous ulcers and lesions after 
continued long-term use (Quattrone et al. 2013). These side effects may become extremely 
relevant in younger patients diagnosed with ET who start hydroxyurea at young ages 
(Quattrone et al. 2013). Hydroxyurea most often affects those tissues with high cellular 
turnover and can lead to startling adverse effects despite doctor’s claims to its safety 
(Quattrone et al. 2013). A study published by Quattrone et al. (2013) shows a multitude of 
cutaneous ulcerations in ET patients caused by underlying vasculopathy to lower 
extremities. The vasculopathy results in increased ulcerations and poor survival rates 
(Quattrone et al. 2013). There are several case studies that have reported cutaneous lesions 
on patients diagnosed with MPNs and started on hydroxyurea. Most of these patients were 
diagnosed relatively young (late 40s to early 50s) and had started long term hydroxyurea 
treatment before the lesions had appeared (Saravu et al. 2006). The span of treatment time 
with hydroxyurea ranged from 2-7 years and had an accumulated dosage of 1-3kg before 
the lesions were found (Saravu et al. 2006). When taken off hydroxyurea, all patients 
demonstrated healing of the ulcers (Saravu et al. 2006). In a review conducted by the Mayo 
Clinic, data showed 14 patients developing ulcers after an average of 6-years use of 
hydroxyurea (Best et al. 1998). Multiple ulcers were shown to have appeared in over half 
the patients and when hydroxyurea was ceased the ulcers healed (Best et al. 1998). While 
not all patients on hydroxyurea develop cutaneous lesions and ulcers, it is clear that after 
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long-term usage patients are at an increased risk of this adverse dermatologic effect 
(Quattrone et al. 2013). The damage caused to DNA repair may play a key role in the 
development of cutaneous ulcers in patient taking hydroxyurea (Quattrone et al. 2013). 
 Some lesser adverse effects caused by hydroxyurea may occur as well. Although 
they are subtle and many are not life threatening, they do appear more commonly than 
cutaneous lesions and acute leukemic transformation. Rodriguez et al. (1998) reported 
patients most often experiencing nausea/vomiting, as well as diarrhea, and less frequently 
neutropenia and thrombocytopenia. The findings suggests that these effects, ranging from 
mild to moderate, appeared in a little over half the patients monitored (Rodriguez et al. 
1998). 
  Hydroxyurea and low-dose aspirin are commonly used together in treatment of ET 
(Tefferi and Barbui 2019). Recent studies have looked into the effect of cytoreduction 
alone vs cytoreduction in combination with low-dose aspirin to analyze the potential risks 
and benefits of the two treatment options. Alvarez-Larrán et al. (2013) conducted one such 
study, viewing 247 high-risk ET who had no prior history of a thrombosis occurrence. The 
occurrence of a thrombosis event was used as the dependent variable to monitor the effect 
of the cytoreduction alone vs the low-dose aspirin and cytoreduction (Alvarez‐Larrán et al. 
2013). Their findings indicated that the likelihood of thrombotic events was reduced 
slightly, but not significantly, by the addition of low-dose aspirin to hydroxyurea (Alvarez‐
Larrán et al. 2013). Patients on cytoreduction alone had an average of 24.4 thrombotic 
events per 1000 person-years while those in the combination therapy had 14.4 events every 
1000 person-years (Alvarez‐Larrán et al. 2013). They then conducted the same study in 
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another cohort aged 60 years and older (Alvarez‐Larrán et al. 2013). The results were 
surprisingly different and showed a significant decrease in thrombotic events for low-dose 
aspirin and cytoreduction treatment together (Alvarez‐Larrán et al. 2013). The event rate 
was 8.6 for the combination vs 29.2 for hydroxyurea alone per every 1000 person-years 
(Alvarez‐Larrán et al. 2013). It was concluded from these data that cytoreductive treatment 
with low-dose aspirin is beneficial in patients with ET over 60 in preventing thrombotic 
events. 
  The same study also reviewed the side-effect risk differences of cytoreduction alone 
vs when paired with low-dose aspirin. Alvarez-Larrán et al. (2013) discovered that the 
threat of major bleeding on low-dose aspirin was a severe problem despite the efficacy in 
preventing thrombotic events. The incidence of bleeding was 14.4 on low-dose aspirin and 
cytoreduction and 1.4 without low-dose aspirin (Alvarez‐Larrán et al. 2013). Similar values 
were reported for the 60 and over cohort. The study showed 12 patients had an incidence 
of major bleeding and two of them died as a result (Alvarez‐Larrán et al. 2013). The 
patients were retrospectively studied with follow ups of 763 person-years for cytoreduction 
and low-dose aspirin and 685 person-years for cytoreduction alone (Alvarez‐Larrán et al. 
2013).  
 
Cytoreductive Treatment Using Anagrelide       
 Anagrelide is the second drug of choice in the event of intolerance to hydroxyurea. 
The mechanism of action by which anagrelide reduces platelet counts in ET patients 
involves megakaryocytes (Tefferi et al. 1997). It appears that anagrelide inhibits 
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megakaryocyte differentiation and produces prolonged phosphorylation of the elF2 by 
potentially inhibiting phosphoprotein phosphatase (Ahluwalia et al. 2015). The prolonged 
phosphorylation of elF2 causes upregulation of downstream signals which induce the 
cellular stress response (Ahluwalia et al. 2015). Induction of the cellular stress response in 
megakaryocytes leads to cellular apoptosis and thus cytoreduction (Ahluwalia et al. 2015). 
This is different from that of hydroxyurea which acts to inhibit early megakaryocyte 
proliferation. Anagrelide may also act through inhibition of the GATA-1 and FOG-1 
upstream regulators associated with megakaryocyte development thus inhibiting the 
production of platelets (Ahluwalia et al. 2015). Increased levels of thrombopoietin, a 
cytokine associated with the regulation of platelet growth, has confirmed this theory. 
Thrombopoietin acts as a ligand, binding to receptors on platelets and undergoing 
endocytosis (Palmblad et al. 2008). Fewer platelets in circulation results in more 
thrombopoietin in circulation (Palmblad et al. 2008). Spencer and Brogden (1994) also 
showed that another mechanism may be key in protecting high-risk ET patients from 
thrombosis. They further examined the effects of anagrelide on platelet aggregation and 
shape. The inhibition of cyclic adenosine monophosphate (cAMP) phosphodiesterase by 
anagrelide decreases the enzymatic breakdown of cAMP raising its level in platelets 
(Spencer and Brogden 1994). Increased cAMP prevented the aggregation of platelets and 
thus decreased risk of thrombosis (Spencer and Brogden 1994). These studies were only 
carried out in animals due to the high dosage required to induce these changes (Spencer 
and Brogden 1994). 
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 Anagrelide undergoes rapid absorption when given orally and its effects and 
adverse reactions are thought to be directly linked to dosage. The starting doses of 
anagrelide vary by country with the United States giving the highest dose of 2.0 mg/day 
and Japan and Europe recommending 1.0 mg/day while even lower doses of 0.5 mg/day 
may be given (Hashimoto et al. 2020). Besses et al. (2012) conducted a study to analyze 
the pharmacokinetics of anagrelide in younger (18-50) vs older (65+) patients. To account 
for dosing differences in patients, the researchers normalized plasma concentrations of 
anagrelide and 3-hydroxy-angrelide to a dose of 1 mg twice daily (Besses et al. 2012). 
Their results indicated that anagrelide had a higher concentration maximum (Cmax) of 3.63 
ng/ml in the older patients than the 2.66 ng/ml shown in younger patients as well as a higher 
area under the curve (AUCT) which was 10.3 ng x h/ml vs 6.4 ng x h/ml respectively 
(Besses et al. 2012). There was no significant difference in anagrelide’s half-life between 
elderly and young patients (Besses et al. 2012). Differences in anagrelide concentrations 
may be due to a lesser first pass effect in elderly patients (Besses et al. 2012). The 
distribution for anagrelide was found to be widespread through-out all tissues with a 
volume distribution (Vd) of about 139-277 L in healthy adults and normalized to 12 L/kg 
(Besses et al. 2012). It is key to note that the first pass metabolism of anagrelide by hepatic 
CYP1A2 produces a more potent active metabolite, 3-hydroxy-anagrelide (Besses et al. 
2012). The bioavailability of oral anagrelide was found to be around 70% and the time to 
peak plasma level was between 1 to 2 hours for both anagrelide and 3-hydroxy-anagrelide 
(Besses et al. 2012). The half-life of anagrelide is 1.7 hours while the half-life of its more 
potent metabolite is 3.9 hours (Wagstaff and Keating 2006). Due to the nature of 3-
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hydroxy-anagrelide it is important to also look at its effects. Besses et al. (2012) found that 
the peak plasma concentration of 3-hydroxy-anagrelide was higher in younger patients with 
a Cmax of 7.26 ng/ml vs 4.19 ng/ml in elderly patients. The AUCT was also higher in younger 
patients, 27.6 ng x h/ml vs 17.4 ng x h/ml seen in the elderly patients (Besses et al. 2012). 
Surprisingly though, the half-life of 3-hydroxy-anagrelide was found to be significantly 
longer in elderly patients (Besses et al. 2012). Clearance of 3-hydroxy-anagrelide is also 
achieved by CYP1A2 (Besses et al. 2012). Their findings indicated, however, that based 
on platelet counts there was no reason to adjust the dosages of anagrelide due to age (Besses 
et al. 2012). Reports for the average time of satisfactory platelet counts were concluded to 
be around 3 to 4 weeks following the initiation of daily dosing (Mazur et al. 2004). 
 The onset time and risk of adverse effects of anagrelide are thought to be directly 
dependent on the dose. In a study by Ito et al. (2019) the efficacy and safety of anagrelide 
was reviewed. They reported slightly lower adverse effects than previous studies and 
theorized the cause to be a slightly lower dosage of 1.44 mg/day unlike other studies which 
used higher dosages (Ito et al. 2019). Anagrelide is often used as the second line defense 
for ET due to its adverse side effects (Tefferi and Barbui 2019). Older patients may 
experience more severe side effects of several types (Wagstaff and Keating 2006). Side 
effects that are commonly seen in patients may range from headaches, nausea, diarrhea, 
and abdominal pain to more severe cardiac effects like palpitations and sometimes heart 
failure (Wagstaff and Keating 2006). The severity of these adverse side effects may 
diminish with continued usage of anagrelide (Wagstaff and Keating 2006). 
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 Anagrelide is one of the more common second-choice alternatives prescribed by 
doctors despite studies proving its noninferiority in the treatment of ET (Tefferi and Barbui 
2019). Its usage as a potential first-line therapy has been studied in the ANAHYDRET and 
EXELS trials comparing hydroxyurea to anagrelide, both alone and in combination with 
aspirin. These two studies were among the largest and most comprehensive, giving rise to 
valuable comparative information on the treatment of ET. The ANAHYDRET study was 
a phase 3 trial examining specifically the claim that anagrelide was equally efficacious and 
as tolerable as hydroxyurea. Their findings confirmed earlier proof that anagrelide is 
noninferior to hydroxyurea (Gisslinger et al. 2013). Over the course of the study, Gisslinger 
et al. (2013) noted that there was no significant difference in the treatment effects of 
anagrelide and hydroxyurea. The study observed 259 patients, 122 taking anagrelide and 
137 taking hydroxyurea, for a total of 730 patient years (Gisslinger et al. 2013). Gisslinger 
et al. (2013) reviewed platelet counts, hemoglobin levels, leukocyte counts, and other 
related ET events at 6 months, 12 months, and 36 months. As compared to hydroxyurea 
treatment, anagrelide resulted in a similar platelet reduction, a slightly greater decrease in 
hemoglobin levels, and no change in leukocyte levels which decreased in the hydroxyurea 
cohort (Gisslinger et al. 2013). The analysis of ET related events revealed that major 
incidences of thrombosis were similar in two groups, 3.32% of anagrelide patents and 
3.42% of hydroxyurea patients (Gisslinger et al. 2013). There was also no significant 
difference between minor events with 10.6% in anagrelide patients and 8.1% in 
hydroxyurea patients (Gisslinger et al. 2013). Gisslinger et al. (2013) did note that there 
was a slight difference in bleeding events, both major and minor, with anagrelide patients 
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having more bleeding events (Gisslinger et al. 2013). The direct mechanism of this side-
effect is unknown, but it is believed that following an overdose of anagrelide, platelet 
function is severely inhibited (Spencer and Brogden 1994). Large doses of anagrelide have 
shown to increase cAMP levels and impair platelet aggregation and shape in animal studies 
resulting in bleeding (Spencer and Brogden 1994).  
 The EXELS study is, to date, the largest study conducted on the treatment of ET 
using anagrelide or hydroxyurea, both in combination with aspirin. A total of 3,598 patients 
were recruited with high-risk ET and monitored in a phase IV study (Jean-Jacques 
Kiladjian et al. 2013). The key focus of the study was to review the safety of long-term 
usage of anagrelide in high-risk ET patients (Jean-Jacques Kiladjian et al. 2013). Results 
of the study showed similar results to the ANAHYDRET study including higher incidence 
of hemorrhage (Jean-Jacques Kiladjian et al. 2013). The EXELS study noted the higher 
hemorrhage rates with anagrelide in combination with low-dose aspirin (Jean-Jacques 
Kiladjian et al. 2013). In an evaluation of EXELS, Birgegard et al. (2014) concluded that 
younger patients were able to tolerate the side effects associated with anagrelide better than 
their older counterparts and continued treatment longer (Birgegard et al. 2014).  
 All of the studies presented comparing anagrelide and hydroxyurea are in an 
agreement that hydroxyurea seems to be the best first-line choice of the two treatment 
options. In the meta-analysis by Samuelson et al. (2006), the researchers point out the key 
issue that the risk of bleeding is significantly increased when anagrelide is used in 
combination with low-dose aspirin. These data were supported by Birgegard et al. (2014) 
as well. The risk of transformation to myelofibrosis may also be increased in treatment 
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with anagrelide and low dose aspirin as shown in the Primary Thrombocythemia 1 study 
(Harrison et al. 2005). The mechanism behind this observation is still unknown and 
deserves further research (Harrison et al. 2005). Conflicting data published by Kellner et 
al. (2020) showed that over a 10-year study span of patients with ET anagrelide had lower 
thrombotic risk, higher overall survival, and higher progression-free cases than 
hydroxyurea and low-dose aspirin. Their results indicated that the lower thrombotic risk 
may be due to the lower incidence of minor thrombotic events in the anagrelide cohort 
(Kellner et al. 2020). The increased incidence of major arterial thrombotic events in the 
anagrelide cohort was theorized to be due to the lack of aspirin usage (Kellner et al. 2020). 
Kellner et al. (2020) also report twice as many hydroxyurea patients transforming to 
myelofibrosis but the Primary Thrombocythemia 1 study showed more patients in the 
anagrelide and low-aspirin group developing myelofibrosis (Harrison et al. 2005). The 
discrepancies in data may be due to the combination therapy of anagrelide and low-dose 
aspirin and patient characteristics (Kellner et al. 2020). 
 
Potential and Current Usage of Interferons in the Treatment of Essential 
Thrombocythemia 
 Interferon- is one of the three main treatments for MPNs despite not being 
approved by the FDA for usage in ET. Clinical trials are currently underway to demonstrate 
the potential usage of interferons for ET. While the exact mechanism of interferons is still 
under some debate, research in recent years have revealed its key role in the treatment of 
MPNs. The mechanism of action through which interferons act is the suppression of 
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hematopoietic progenitor cell differentiation (Birgegård 2016). Interferon- is the type 1 
interferon that is most often used in treatment (J.-J. Kiladjian, Chomienne, and Fenaux 
2008). Interferon- has many target actions that may explain efficacy for MPNs. Those 
actions include suppression of megakaryopoiesis and the hematopoietic progenitors for 
erythrocytes and granulocytes (Stein and Tiu 2013). This action induces cytoreduction of 
platelets and has been shown to reduce the JAK2V617F allelic burden (ratio of mutant 
genes to wild-type genes) that is sometimes associated with ET (Stein and Tiu 2013). As 
previously discussed in the section on mutations and molecular mechanisms of ET, 
interferons act as key signals for the activation of the JAK/STAT pathways (Hubbard 
2018). The JAK2V617F mutation produces hematopoietic stem cells that are 
hypersensitive to interferon- (Bywater et al. 2019). This hypersensitivity creates 
enhanced STAT1 signaling during interferon- treatment (Bywater et al. 2019). Bywater 
et al. (2019) theorized the mechanistic reduction of the JAK2V617F allelic burden to be 
induced by interferon- causing DNA damage to the JAK2V617F hematopoietic stem cells 
via specific activation of reactive oxygen species. In addition to the reduction of the 
JAK2V617F allelic burden, Kiladjian et al. (2008) showed the megakaryocytic lineage also 
had a unique specificity for interferon-. Treatment with interferon- inhibited 
thrombopoietin-induced signaling and thus decreased megakaryopoiesis (J.-J. Kiladjian, 
Chomienne, and Fenaux 2008). The inhibition and decrease of the megakaryocytes are 
associated with morphological and biochemical changes (J.-J. Kiladjian, Chomienne, and 
Fenaux 2008). This sensitivity to interferon- also resulted in suppression of the MPN 
clones via an immune response (J.-J. Kiladjian, Chomienne, and Fenaux 2008). The action 
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of interferon- is unique compared to anagrelide and hydroxyurea in that it may not only 
alter morphologies of megakaryocyte clones, but it may also lead to an immune response 
against the MPN clones. 
 The efficacy of interferon- is similar to both those of anagrelide and hydroxyurea 
in terms of platelet reduction, but the onset of action my take longer (Birgegård 2016). 
Interferon- has a high bioavailability after parenteral administration (Radwanski et al. 
1987). The distribution for interferon- is relatively similar to hydroxyurea but smaller 
than that of anagrelide at a mean estimate of 12 to 40 L (without a given bodyweight) and 
normalized for body weight at 1.4L/Kg in patients with hepatitis C (Radwanski et al. 1987). 
Lengfelder et al. (1996) reported that a daily dose of 3 mill IU produced a successful 
cytoreductive response in 90% of patients. In long-term maintenance studies of interferon-
 it was found that of 35 patients who began 6-month induction period with 21 mill IU 
90% of them had weekly platelet values under 600 x 109/L (Lengfelder, Griesshammer, 
and Hehlmann 1996). After the induction period they were placed on a maintenance 
program of 3 mill IU (Sacchi et al. 1991). Of the 35 patients 24% were required to take it 
daily, 61% only took it 3 times a week, and 15% took it once a week (Sacchi et al. 1991). 
Given that interferon- has no oral formulation and must be administered via injection, 
adherence may be a disadvantage with this treatment form. The bioavailability of each 
injection area will also differ dependent on where it is injected. Intramuscular (IM) is 83%, 
subcutaneous (SubQ) is 90%, and intravenously is just under 100% (Radwanski et al. 
1987). Radwanski et al. (1987) also demonstrated that 30 minutes after intravenous 
injection, interferon- was distributed very rapidly with a distribution half-life of 2 hours. 
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The intramuscular and subcutaneous injections showed absorption half-lives of 2 to 3 hours 
(Radwanski et al. 1987). After the starting dose of 5 x 106 IU/m2, interferon- has an 
intramuscular Cmax of 42.1 IU/ml at six hours and a subcutaneous Cmax is 45.5 IU/ml at 
eight hours (Radwanski et al. 1987). Radwanski et al. (1987) also noted the elimination 
half-lives to be 2.2 hours intramuscularly and 2.9 hours subcutaneously (Radwanski et al. 
1987). The clearance of interferon-, while little is known about the mechanism, is roughly 
2 times that of the glomerular filtration rate and the drug has been found in the urine of test 
animals (Radwanski et al. 1987). 
 Adverse side effects from interferon- has contributed to 20-25% of the patient 
non-adherence rates in ET (Birgegård 2016). Kiladjian et al. (2008) also reported similar 
data showing a non-adherence rate of 25% in patients with ET taking interferon-. Of this 
25%, 12.5% of them experience side effects within the first year to cause the cessation (J.-
J. Kiladjian, Chomienne, and Fenaux 2008). They have shown that the most common 
adverse side effects are flu-like symptoms ranging from headaches and body aches to 
fevers and fatigue (J.-J. Kiladjian, Chomienne, and Fenaux 2008). The symptoms are dose 
dependent and can start 1 to 3 hours after injection with a decrease in intensity within 
several weeks (J.-J. Kiladjian, Chomienne, and Fenaux 2008). Hematological toxicity is 
rarely reported in patients with ET. Patients most frequent reasons for withdrawal from 
interferon- treatment are the muscle aches and fatigue (J.-J. Kiladjian, Chomienne, and 
Fenaux 2008). Other less frequent side effects that patients report are anxiety, depression, 
and mood changes, which may affect patients’ social environments (J.-J. Kiladjian, 
Chomienne, and Fenaux 2008). There have also been reports of skin irritations, 
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autoimmune abnormalities, and in some cases cardiac and neurological toxicities (J.-J. 
Kiladjian, Chomienne, and Fenaux 2008).  
 Through advancements in pharmaceuticals, the pegylation of interferon- 2a has 
made vast improvements in the administration and side effects experienced by patients (J.-
J. Kiladjian, Chomienne, and Fenaux 2008). Due to the slower clearance of pegylated 
interferon- 2a, the drug effect lasts longer and therefore the regimen only requires a 
dosage once per week (Glue et al. 2000) Glue et al. (2000) showed the half-life to be 4.6 
hours and the clearance one-tenth that of non-pegylated interferon. They concluded that 
once weekly injections were enough to sustain the treatment regimen and needed serum 
levels (Glue et al. 2000). Side effects and adverse events also showed a notable difference 
between nonpegylated interferon- and the pegylated version (Glue et al. 2000) Yacoub et 
al. (2019) performed the largest study to date to investigate pegylated interferon- 2a in high 
risk ET patients who had intolerance to hydroxyurea. Their review on the safety of 
pegylated interferon- 2a revealed that the discontinuation rates in several studies 
reviewing the treatment ranged from 13.9% to 24.3% (Yacoub et al. 2019). The data 
indicated that the lower the dosage the fewer discontinuations (Yacoub et al. 2019). As far 
as adverse events anemia was the most common hematological type and abdominal pains 
were the most common non-hematological form (Yacoub et al. 2019). Of the 65 patients, 
40 discontinued treatment due to study closure or treatment completion, 7 were 
discontinued due to adverse effects, and 7 more were discontinued due to disease 
progression, indicating the majority of patients were able to complete the study without 
severe side effects (Yacoub et al. 2019). While the elimination of adverse side effects has 
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still yet to be seen in the treatment of ET with interferon-, there is clear evidence that the 
pegylation of interferon- may show promise in the reduction of the most severe adverse 
effects. Some flu-like symptoms still persisted in the pegylated version of interferon-, but 
patients reported more tolerability than previously recorded in safety studies (Gowin et al. 
2017). Samuelsson et al. (2006) warns, that while some studies indicate mildly adverse 
effects, their experience in the field and previous studies of anagrelide showed that patients 
have a tendency to report higher adverse effects. Their study revealed a 50% dropout rate 
for pegylated interferon- 2a (Samuelsson et al. 2006).  
 In more recent years a monopegylated version called Ropeginterferon- 2b has 
been introduced in clinical trials as well. Pegylated interferon- 2a contains a polyethylene 
glycol chain on the interferon- (Zalipsky 2020). The molecule itself weighs roughly 40 
kDa (Zalipsky 2020). The ropeginterferon- differs from the pegylated version in that a 
single polyethylene glycol chain is attached to a proline which is added to the interferon- 
(Zalipsky 2020). The molecular weight is 60 kDa (Zalipsky 2020).   
The route of administration is still an injection but now patients are given a prefilled 
pen which can be taken home for ease of administration and increase in adherence rates 
(How and Hobbs 2020). The half-life of ropeginterferon is 6-10 days subcutaneously and 
allows for a bi-weekly schedule of dosing (Gisslinger et al. 2016) . Adverse effects were 
mild compared to those of interferon and pegylated interferon and the discontinuation rate 
was only 8% (Gisslinger et al. 2016). The adverse effects that did occur were mild flu-like 
symptoms, fatigue, thrombocytopenia, and leukopenia as well as abnormalities in liver 
function test (Gisslinger et al. 2016). Ropeginterferon-  2b is currently under review for 
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a biological license application by the FDA. This would make it the first interferon 
approved and developed for treatment of MPNs (How and Hobbs 2020).      
 Studies recently involving the comparison of hydroxyurea and interferon- have 
shed light on the possibility of interferon- as a treatment standard for ET and even first-
line therapy in younger and pregnant patients (Barbui et al. 2018). Studies reviewing 
hydroxyurea and interferon usage have shown that unlike hydroxyurea treatment, treatment 
with interferons have been reported to reduce allelic burdens (ratio of mutant genes to wild-
type genes) of CALR and JAK2V617F mutations in hematopoietic stem cells. In some 
cases the JAK2V617F allelic burden was reported as undetectable in these cells and 
remained even so with the cessation of treatment (Foucar and Stein 2017). Mascarenhas et. 
al (2016) in an interim analysis noted that there is no significant difference in the 
hematologic response between hydroxyurea and interferon treatment. More analysis would 
be needed on adverse effects and quality of life to determine a difference in first line 
therapy (J. O. Mascarenhas et al. 2016). In a more recent study, Yacoub et al. (2019) 
evaluated the efficacy of pegylated interferons in the event of intolerance to hydroxyurea 
and found them to be beneficial but questioned the toxicity profile. They concluded that 
while interferons are a good resource for high-risk ET patients that are intolerant to 
hydroxyurea, it is necessary for patient screening and gradually increasing dosage for the 
management of adverse events (Yacoub et al. 2019). Other studies have shown an even 
greater efficacy for interferons when used in combination with ruxolitinib, a janus kinase 
inhibitor (Hasselbalch and Holmström 2019). It is key to note that unlike hydroxyurea, 
interferon has not been reported to cause leukemic transformation and malignancies 
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associated with its use (Zhang and Duan 2014). In their study, Zhang and Duan (2014) 
showed that in comparison to hydroxyurea, interferon- showed increased hematologic 
remissions, lower chance of thrombosis, as well as possible induction of remission on a 
molecular level in JAK2V617F + patients (Zhang and Duan 2014). Lane and Mullally 
(2013) reported similar results in JAK2V617F + patients as well, showing molecular 
remission and possible eradication of the JAK2 long-term hematopoietic stem cells (Lane 
and Mullally 2013). Another study by Verger et al. (2015) showed significant 
hematological responses in patients with CALR mutations as well as JAK2 (Verger et al. 
2015). These recent studies on the usage of interferons indicate a key resource for the 
treatment of ET. The ability of interferons to reduce mutational allelic burdens occurs a on 
molecular level and is an extremely useful tool for the long-term control of ET. More 
research is needed on peginterferon and ropeginterferon in order to fully understand the 
risks and benefits of this drug class. 
      
Investigational Treatment of Essential Thrombocythemia with Janus Kinase 
Inhibitors  
 Janus kinase inhibitors are currently under investigational review for the treatment 
of MPNs and ET (Geyer and Mesa 2014). Ruxolitinib is the most recent and currently only 
janus kinase inhibitor still under-going evaluation and clinical trials for the treatment of 
ET and PV (Geyer and Mesa 2014). Current uses of janus kinase inhibitors are for the 
treatment of myelofibrosis, a disease often associated with the progression of ET into more 
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severe symptoms. Ruxolitinib has been approved for this indication in the United States 
(Geyer and Mesa 2014). 
 The mechanism of action of janus kinase inhibitors for MPNs is thought to be 
through selectively inhibiting JAK signal transduction (Cazzola and Kralovics 2014). The 
JAK2 subclass of janus kinases is the most important in MPNs because this is the location 
of the JAK2 V617F mutation (Cazzola and Kralovics 2014). It appears that no matter which 
mutation is present, the JAK-STAT pathway is overly active in the megakaryocytes of 
these MPNs (Cazzola and Kralovics 2014). Activation of growth and differentiation of 
megakaryocytes occurs via the coupling of cytokine ligand-binding to extracellular JAK 
and the intracellular tyrosine phosphorylation (Hubbard 2018). The auto-phosphorylation 
of the two JAK dimers leads to activation of the STAT pathway and hematopoietic cell 
phosphatase (Hubbard 2018). Once the STAT pathway is activated, changes in 
transcription factors occur to upregulate the proliferation of hematopoietic stem cells 
(Hubbard 2018). Hematopoietic cell phosphatase is an enzyme that serves as a negative 
feed-back regulator to decrease the growth of hematopoietic stem cells (Ihle et al. 1994). 
The JAK inhibitors are designed to act specifically via induced fit at an ATP-binding site 
that is unique to the JAK2 family (Lucet et al 2006). Binding of the inhibitor prevents the 
activation loop from opening to expose the activation site and thus the inhibitor fits into 
the active site and stops the activation of JAK2 (Lucet et al. 2006). Ruxolitinib is an 
important JAK inhibitor because it inhibits the JAK2/JAK1 complex selectively at JAK2 
(Verstovsek et al. 2010). 
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 Ruxolitinib is given orally making it easy for patients to maintain the daily dosing 
schedule. In two recent Phase III trials on ruxolitinib the maximum dosage given was 20 
mg twice daily (Mesa, Yasothan, and Kirkpatrick 2012). The FDA dosing label 
recommends the dosing be determined by platelet counts, 20 mg twice daily for platelet 
counts higher than 200 X 109/L and 15mg twice daily for lower counts. As the platelet 
counts decline every 25 X 109/L so should the dosage decline by 5mg each time until the 
desirable platelet count is achieved at which point the dosing is continued at the same 
amount (“US Food and Drug Administration" 2011) .  
In recent clinical trials of ruxolitinib the pharmacokinetics of the drug were 
determined in healthy volunteers. The oral bioavailability was determined to be high (Shi 
et al. 2011). The time to peak plasma concentration after oral ingestion is 1 to 2 hours and 
the drug in plasma is 97% bound to albumin (Shi et al. 2011). The volume of distribution 
is found to be between 1.0 and 1.94 L/Kg at steady state in healthy individuals (Shi et al. 
2011). Ruxolitinib is metabolized via CYP3A4 into two active metabolites (J. Mascarenhas 
and Hoffman 2012). The half-life of ruxolitinib alone is 3 hours while total half-life 
including the metabolites is 5.8 hours. Clearance of the drug differs between men (17.7 
L/h) and women (22.1 L/h) and is lower in PV patients (12.7 L/h) (J. Mascarenhas and 
Hoffman 2012). According to the FDA drug label on ruxolitinib, in the two Phase III 
clinical trials that were performed, adverse effects such as thrombocytopenia, anemia, and 
neutropenia were seen as early as 6 weeks into the treatment (“US Food and Drug 
Administration" 2011). The length of time for desired platelet counts to be achieved 
occurred within 8 weeks (David Green 2017). 
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 Recent data has shown that JAK2 inhibitors may have limited efficacy in MPN 
patients including those with ET. Vannucchi and Harrison (2017) explain in their study on 
the emerging treatments for MPNs that results with JAK2 inhibitors have been bleak. In 
early Phase I and II clinical trials either the efficacy of the JAK2 inhibitors was low or the 
toxicities limited the length of time a patient could adhere (Vannucchi and Harrison 2017). 
JAK2 inhibitors like fedratinib and pacritinib were placed on hold after clinical trials in 
primary myelofibrosis (PMF) raised safety concerns (Vannucchi and Harrison 2017). 
Adverse side-effects like Wernicke’s encephalopathy, increased bleeding, and cardiac 
events were seen in treatment using these drugs (Vannucchi and Harrison 2017). 
Ruxolitinib was selected for clinical trials with ET due to an increased survival advantage 
of PMF patients and the reduction in thrombotic events in PV patients (Vannucchi and 
Harrison 2017). The limited side-effect profile in the treatment of PMF and PV with 
ruxolitinib raised no concern for the safety of patients (Vannucchi and Harrison 2017). The 
COMFORT-I and COMFORT-II studies, however, both showed that due to adverse effects 
and lack of efficacy over half of the patients discontinued ruxolitinib in 3 years and 25% 
more discontinued after 5 years (Schain et al. 2019). After the discontinuation of ruxolitinib 
in this study, treatment options were limited to hydroxyurea and glucocorticoids (Schain 
et al. 2019). Another key problem with JAK2 inhibitors is that most are not specific to 
JAK2 and may also block JAK1 and JAK3. This could lead to more severe side effects like 
anemia (Dahlström et al. 2020). Momelotinib is another JAK inhibitor that has shown 
limited potential in the treatment of MPNs. Like ruxolitinib, momelotinib is a selective 
JAK1 and JAK2 inhibitor, however, momelotinib has no difference in affinity for JAK1 or 
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JAK2 (Verstovsek et al. 2017). In a phase II study on the treatment of ET and PV using 
momelotinib, patients were given 100 mg and 200 mg orally once daily (Verstovsek et al. 
2017). The study showed that only 2 patients with PV met the criteria for an efficacious 
treatment and none of the ET patients met the criteria (Verstovsek et al. 2017). This study 
demonstrated the limited efficacy of momelotinib in the treatment of ET and PV 
(Verstovsek et al. 2017). 
 Current studies are reviewing the treatment of high-risk ET patients with 
ruxolitinib. These patients are typically intolerant to hydroxyurea and often are on a last 
treatment effort. In a phase II study of ruxolitinib, 24 of the 39 patients monitored continued 
treatment after the study cutoff (Verstovsek et al. 2014). The study showed ruxolitinib 
decreased platelet counts and 13.2% showed significant reduction in platelet counts below 
400 X 109/L (Verstovsek et al. 2014). Ruxolitinib was also efficacious in the reduction of 
white blood cells and splenomegaly associated with ET (Verstovsek et al. 2014). In the 
MAJIC-ET phase II study the results indicated that ruxolitinib was less efficacious than 
hydroxyurea and that it should remain a second-choice treatment option (Gunawan et al. 
2018). One valuable asset of ruxolitinib that was noted was the decrease in symptom 
prevalence, frequency, and severity, termed the symptom burden, by 32% as compared to 
the 0% of hydroxyurea in the MAJIC-ET study (Gunawan et al. 2018). Another study 
showed that in a one-year treatment with ruxolitinib, the 16 high-risk ET and PV patients 
had no reports of thrombotic events and the reduction of platelets allowed PV patients to 
cease phlebotomy treatments (Ekinci and Merter 2019). However, in elderly patients there 
was an increased risk of serious infection and development of pneumonia did occur in 2 
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patients (Ekinci and Merter 2019). Treatment of ET with JAK inhibitors is still an open 
topic of research due the potential shown by ruxolitinib. While many JAK inhibitors, like 
fedratinib and pacritinib, have been removed from clinical trials due to adverse effects and 
low efficacies, ruxolitinib have proven of some value in the treatment of ET. It is clear that 
more research is needed on JAK inhibitors and their potential role in the treatment of ET. 
 
Study Reference  Drug Outcome 
COMFORT-I (PV and 
ET) 
Schain et al. 2019 Ruxolitinib Not efficacious due to 
adverse side effects 
COMFORT-II (PV and 
ET) 
Schain et al. 2019 Ruxolitinib Not efficacious due to 
adverse side effects 
Verstovesk et al. 2010 Verstovesk et al. 2010 Ruxolitinib Not efficacious due to 
adverse side effects 
Verstovesk et al. 2009 Verstovesk et al. 2009 Pacritinib Discontinued Clinical 
trials due to severe 
adverse effects 
Verstovesk et al. 2017 
(PV and ET) 
Verstovesk et al. 2017 Momelotinib Not efficacious in ET 
patients 
Table 3. Overview of JAK Inhibitor Clinical Trials. The table above illustrates the 
different clinical trials of recent JAK inhibitors in the treatment of MPNs. The data is 
adapted from Sonbol et al. 2013. 
 
Imetelstat and the Potential of Telomerase Inhibition in the Treatment of Essential 
Thrombocythemia 
 Imetelstat is a telomerase inhibitor that is of potential use in the treatment of ET. 
Telomerase is a key enzyme in MPNs causing the malignant properties of cancers 
(Dahlström et al. 2020). In normal human differentiated cells telomerase is a silent RNA-
dependent polymerase that can cause cancers when active through telomere lengthening 
(Dahlström et al. 2020). The catalytic component of telomerase is called telomerase reverse 
transcriptase (TERT) and it is key in the development and progression of cancers 
(Dahlström et al. 2020). TERT has been shown to be active in megakaryocytes of patients 
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who have been diagnosed with ET (Baerlocher et al. 2019). This leaves a clear mechanism 
of action for imetelstat in the treatment of ET. Baerlocher et al. (2019) determined that 
imetelstat acts to suppress the growth of megakaryocytes in ET patients and its effect is 
independent of mutation form or previous treatments. They theorized the mechanism of 
action to be uniquely linked to the increasing levels of TERT seen in ET patients and the 
effects of imetelstat consistently decreased TERT through-out the study of ET patient cells 
(Baerlocher et al. 2019). 
 Baerlocher et al. (2019) assessed the efficacy and safety of imetelstat in the 
treatment of ET. In their study they administered imetelstat intravenously to 18 patients 
with 7 receiving a starting dose of 7.5 mg/kg and 11 receiving 9.4 mg/kg (Baerlocher et al. 
2019) . The data showed the hematologic response rate to be 100% (platelet count lower 
than 600 x 109/L) and a complete response rate (platelet count lower than 400 x 109/L) rate 
was achieved in 16 patients within 6 weeks of initial dosing (Baerlocher et al. 2019). The 
higher dosage correlated with quicker response times (Baerlocher et al. 2019). Long-term 
data indicated that intermittent dosing was required to maintain the hematologic response 
(Baerlocher et al. 2019). While imetelstat did reduce the allelic burden of all mutations, it 
appeared to be more proficient in the reduction of JAK2 V617F mutated patients 
(Baerlocher et al. 2019). The main concern for adverse effects were fatigue, nausea, 
abnormal liver function, and neutropenia (Baerlocher et al. 2015). Research by Dahlström 
et al. (2020) suggests the possible combining of JAK inhibitors and telomerase inhibitors 
for the treatment of ET. Their data were validated by an increase in CD34+ cells from the 
JAK inhibitors that were blocked by the addition of telomerase inhibitors (Dahlström et al. 
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2020). It is believed that JAK inhibitors act on gene KLF4 increasing its expression to 
induce cytoreduction but, the increased expression may lead to an induction of cells to de-
differentiate to CD34+ leukemic stem cells. In the first 9 weeks of treatment with JAK 
inhibitors CD34+ cells rose from 2% to 90% (Dahlström et al. 2020). The addition of 
telomerase inhibitors is theorized to target the telomerase of these cells and decrease the 
JAK inhibitor induced CD34+ effect (Dahlström et al. 2020). The exact mechanism by 
which this occurs is still under review. More data are needed to verify this, but researchers 
hypothesize that telomerase inhibitors may decrease the adverse side-effects associated 

















Based on the FDA drug labels and data collected from clinical studies, a 
comparative table of the key drugs for the treatment of ET has been composed. It is 
important to note that some of the data obtained for the table came from clinical trials on 
MPNs. PV and ET are very similar in treatment and outcome and therefore clinical trials 
are easily comparable and in certain instances interchangeable. The data for ruxolitinib 
mostly pertained to patients of post-ET and post-PV who were in the myelofibrosis stage. 
These data are still relevant to this thesis because most patients in the late phase of ET and 
PV have exhausted all other treatment options and therefore ruxolitinib is a treatment of 
last resort for these patients. Current studies on ruxolitinib in the treatment of ET are still 
ongoing. Momelotinib was not included in the comparison chart due to its lack of efficacy 
in the treatment of ET during phase II studies. 
Of the three orally administered drug, hydroxyurea, anagrelide, and ruxolitinib, 
hydroxyurea has the highest bioavailability. Unlike these low molecular weight drugs that 
can be given orally, the interferon class has a high molecular weight limiting its 
administration to injections via doctor visits. Oral drugs have an increased adherence to 
dosing regimens due to self-administration. The delivery device for ropeginterferon tries 
to solve this problem, as it is a refillable pen that can be self-administered bi-weekly at 
home instead of a clinic visit.  
Hydroxyurea and anagrelide’s hematologic effects are both seen within a month of 
administration, whereas the effects of the interferon class occur more slowly, averaging 
around 2 to 3 months for high-risk patients (David Green 2017). Anagrelide and ruxolitinib 
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achieve peak plasma concentrations the most rapidly of the oral drugs and anagrelide also 
has the shortest elimination half-life. However, the breakdown of anagrelide and ruxolitinib 
into active metabolites prolongs their pharmacodynamic effects. The clearance of both 
anagrelide and ruxolitinib is mediated in the liver by CYPs, which increases risk of adverse 
effects and toxicity due to drug interactions. While the complete mechanism of clearance 
is unknown for hydroxyurea, it is theorized to use a hepatic route that may become 
saturable, increasing the risk of toxicity as well.  
Pegylated interferon and ropeginterferon have the slowest clearances, leading to 
sustained serum levels for longer periods of time, so that they require less frequent 
maintenance dosing compared to other drugs. Adherence will decrease with increased 
frequency of dosing. It is key to note that most patients with ET are elderly and an increase 
in dosing frequency will be harder to remember, involve more trips to pharmacies, and lead 
to an over-all decrease in the adherence to the drug. Pegylated interferon may have a once 
weekly dosing schedule, but it does require frequent doctor visits for injections. The table 
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Table 4. Comparison of Drugs for Treatment of ET. The table above provides the key 
pharmacokinetic and pharmacodynamic differences between treatment options for ET. 
Data for Hydroxyurea: Rodriguez et al. 1998 and “Drugs@FDA: FDA-Approved Drugs” 
n.d. Data for anagrelide: Besses et al. 2012 and Mazur et al. 2004 Data for Interferon-: 
Radwanski et al. 1987 and García-García et al. 2016. Data for pegylated interferon- 2a: 
Glue et al. 2000 and Brennan, Xu, and Grippo 2012. Data for ropeginterferon- 2b: 
Gisslinger et al. 2016 and How and Hobbs 2020. Data for ruxolitinib: Shi et al. 2011 and 




 Patient characteristics are an important consideration in the choice of treatment for 
ET. Hydroxyurea and low-dose aspirin are better suited treatments for the standard ET 
patient. They are diagnosed at an elderly age, typically 60+ years of age, and some form of 
risk factor, such as a history of thrombosis. This classifies them in a high-risk ET category. 
However, not all patients fit this mold, for younger patients or those that are pregnant 
hydroxyurea is not the best option. Its long-term effects, while not clearly defined in 
elderly, may be potentiated in younger patients leading to leukemic transformation and 
cutaneous lesions. The best option for these patients appears to be anagrelide or interferons. 
  JAK inhibitors, like ruxolitinib, are the only treatment form that show inferiority 
to hydroxyurea when used in monotherapy in comparison studies. This inferiority is 
thought to remedied by the addition of telomerase inhibitors like imetelstat (Dahlström et 
al. 2020). When comparing the treatment options of ET for adverse effects, it is best to 
compare them to hydroxyurea as a base for the best available therapy to date. In a meta-
analysis by Samuleson et al. (2015) anagrelide was proven to be inferior to hydroxyurea in 
an overall risk assessment of thrombosis, rates of major bleeding, and death outcome. The 
table below gives a visual representation of data collected from 3 of the most important 
anagrelide vs hydroxyurea studies up to date. The results indicate that hydroxyurea is 
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6.7% of patients  
Anagrelide: 7.7% 





Table 5. Comparison of Hydroxyurea and Anagrelide Studies. The data above shows 
the incidence of thrombosis, major bleeding, and death outcome during two studies of 
anagrelide vs hydroxyurea. The death outcome in both studies was stratified to disease 
related vs unrelated death. Gisslinger et al. (2013) demonstrated that anagrelide was non-
inferior to hydroxyurea in efficacy but adverse events were shown to be worse with 
anagrelide. Based on the data collected anagrelide is the inferior drug to hydroxyurea in 
terms of adverse effects. 
 
 While studies directly comparing hydroxyurea to interferons in efficacy have yet to 
be fully presented, there are some data indicating that hydroxyurea is superior to 
interferons. Adherence rates are indicative of the quality of life a patient is experiencing 
while taking a drug. High non-adherence rates may indicate that the drug is causing severe 
adverse events causing the patients to cease treatment. Multiple studies have reported the 
drop-out rate to be as high as 55% in a cohort of patients with PV and ET taking 
cytoreductive drugs (Le Calloch et al. 2018). Despite the high hematological response rates 
and reduced allelic burden, the reports of fatigue and other flu-like symptoms appear to 
dissuade most patients from continuing on with this form of treatment. 
In the treatment of ET with JAK inhibitors, studies have concluded that 
hydroxyurea is the superior treatment. Studies show that the efficacy of JAK inhibitors is 
lacking in comparison to hydroxyurea (Dahlström et al. 2020). The addition of telomerase 
inhibitors, like imetelstat may increase the efficacy by reducing the CD34+ build up that 
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associated with JAK inhibition. On its own imetelstat has yet to be compared to 
hydroxyurea in full comparison studies. Imetelstat is given intravenously making it less 
likely to be adhered to by patients. The hematologic rates were 100% in ET patients on 
combination therapy with JAK inhibitors but adverse side effects were present with higher 
doses (Baerlocher et al. 2015). It is key to note that more data is needed to formulate any 
further conclusions about imetelstat and JAK inhibitors in comparison to hydroxyurea. 
While some studies have been published, there are not enough results to from a conclusive 

















FUTURE STUDIES AND RESEARCH 
 
 There is clear need for additional research on the treatment of ET. Hydroxyurea is 
currently the best option for treatment, but as prevalence of ET rises and younger patients 
are diagnosed there needs to be more treatment options with few side effects. 
Ropeginterferon shows promising results for the long-term treatment of ET, but not enough 
studies have been completed to show a comparison of safety and efficacy to hydroxyurea. 
Interferons are the most promising forms of treatment due to their sustained activity and 
immunological response for long-term treatment in conjunction with their hematologic 
response. However, the need for parenteral injection is a limitation and given the very high 
molecular weight of the drug class an alternative route of administration is unlikely.  
More data are also needed on the effects of differing mutational profiles on the 
appropriate choice of treatments. There has been very little data to date that indicate any 
difference in treatment based on the mutation type in ET patients. Data indicate that 
differences in mutations may result in different subtypes of ET, as shown with slightly 
higher platelet counts and prevalence in one gender over the other in those with CALR 
mutations. It has also been noted that the JAK2 V617F mutation has higher transformation 
rates to PV and post-ET than the other mutations. These differences need to be further 
investigated to determine how symptom burden, drug of choice, and dosing affect the 







 With all factors considered the best available therapy for the treatment of ET is 
hydroxyurea and low-dose aspirin. This treatment method is useful for the majority of ET 
patients, considering the typical diagnosis of ET is in elderly patients. The toxicity profile 
is relatively low, and the chance of severe adverse effects is less than with other available 
therapies. Any cutaneous lesions that may present themselves usually occur after extended 
long-term use and are typically found in patients who start hydroxyurea treatment at 
younger ages. Non-adherence to hydroxyurea due to adverse events is less common than 
in any other treatment form. Hydroxyurea is also key a treatment for ET due to its relatively 
rapid hematologic response and cytoreductive effect. The combinational therapy of 
hydroxyurea and low-dose aspirin produces the most uniform response of reducing 
thrombotic events and increasing the quality of life for the patient.  
In the event that a patient is of younger age or pregnant or intolerant to hydroxyurea, 
treatment with interferons appears to be the next best option. While the route of 
administration and flu-like side effects may deter some patients and doctors from this 
treatment, the benefits out-weigh the risks. Despite its toxicity profile, interferons are the 
only treatment option that are known to have no leukemogenic effects and whose safety 
profile has been evaluated and approved for pregnant women. They also hold key value in 
an immunological attack on the JAK2 V617F hemopoietic stem cells for long-term 
treatment. Advances in the treatment of ET with interferons is making progress with 
increased time between maintenance doses for ropeginterferon with a delivery device for 
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patient self-administration. Treatment by interferons gives the patient the next best quality 
of life relative to the standard treatment of hydroxyurea and low-dose aspirin. 
Anagrelide should serve as a last choice option in the event of hydroxyurea 
intolerance or lack of response to interferons. It shows similar efficacy to that of 
hydroxyurea with hematologic responses. Anagrelide almost rivals hydroxyurea in the 
prevention of thrombotic events, but the adverse effects are slightly worse. The 
combinational therapy of anagrelide and low-dose aspirin causes high bleeding rates and 
should be monitored frequently. Anagrelide and low-dose aspirin should not be used 
together as an initial form of second-line treatment but rather the patient should be started 
on anagrelide and monitored from there for signs of improvement. Should no signs of 
improvement be seen, the patient may be administered low-dose aspirin. 
In conclusion it is in the best interest of the patient for the doctor to take a full-scale 
work-up of the patient before prescribing any treatment for ET. All factors including age 
of diagnosis and length of treatment should be considered as well as allelic mutation 
burdens. Hydroxyurea and low-dose aspirin remain the current gold-standard of treatment 
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